CDTX vs. AGTC, NTGN, XFOR, CHRS, SCLX, CGEN, CMPX, GLUE, IVVD, and FENC
Should you be buying Cidara Therapeutics stock or one of its competitors? The main competitors of Cidara Therapeutics include Applied Genetic Technologies (AGTC), Neon Therapeutics (NTGN), X4 Pharmaceuticals (XFOR), Coherus BioSciences (CHRS), Scilex (SCLX), Compugen (CGEN), Compass Therapeutics (CMPX), Monte Rosa Therapeutics (GLUE), Invivyd (IVVD), and Fennec Pharmaceuticals (FENC). These companies are all part of the "medical" sector.
Applied Genetic Technologies (NASDAQ:AGTC) and Cidara Therapeutics (NASDAQ:CDTX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, community ranking, institutional ownership, earnings, profitability, risk, analyst recommendations and dividends.
Applied Genetic Technologies has a net margin of 0.00% compared to Applied Genetic Technologies' net margin of -73.46%. Cidara Therapeutics' return on equity of -192.90% beat Applied Genetic Technologies' return on equity.
Cidara Therapeutics has a consensus price target of $71.25, indicating a potential upside of 461.47%. Given Applied Genetic Technologies' higher possible upside, analysts plainly believe Cidara Therapeutics is more favorable than Applied Genetic Technologies.
Cidara Therapeutics has higher revenue and earnings than Applied Genetic Technologies. Cidara Therapeutics is trading at a lower price-to-earnings ratio than Applied Genetic Technologies, indicating that it is currently the more affordable of the two stocks.
22.1% of Applied Genetic Technologies shares are owned by institutional investors. Comparatively, 35.8% of Cidara Therapeutics shares are owned by institutional investors. 4.1% of Applied Genetic Technologies shares are owned by company insiders. Comparatively, 7.4% of Cidara Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Cidara Therapeutics received 6 more outperform votes than Applied Genetic Technologies when rated by MarketBeat users. Likewise, 70.24% of users gave Cidara Therapeutics an outperform vote while only 64.72% of users gave Applied Genetic Technologies an outperform vote.
Applied Genetic Technologies has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Cidara Therapeutics has a beta of 1.11, indicating that its share price is 11% more volatile than the S&P 500.
In the previous week, Cidara Therapeutics had 4 more articles in the media than Applied Genetic Technologies. MarketBeat recorded 4 mentions for Cidara Therapeutics and 0 mentions for Applied Genetic Technologies. Applied Genetic Technologies' average media sentiment score of 0.87 beat Cidara Therapeutics' score of 0.34 indicating that Cidara Therapeutics is being referred to more favorably in the news media.
Summary
Cidara Therapeutics beats Applied Genetic Technologies on 12 of the 18 factors compared between the two stocks.
Get Cidara Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CDTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cidara Therapeutics Competitors List
Related Companies and Tools
